Cyclosporine and experimental skin allografts: Long-term survival in rats treated with low maintenance doses

E. Towpik, J. W. Kupiec-Weglinski, Douglas Tyler, J. L. Araujo, T. M. Schneider, D. Araneda, G. M. Murphy, N. L. Tilney

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Although cyclosporine (CsA) is a powerful immunosuppressive agent in organ transplantation, its efficacy in skin transplantation has not been examined completely. We have tested it as primary immunosuppression in a rat skin allograft model. Histoincompatible Brown-Norway skin grafts are rejected in untreated Lewis hosts within 9 ± 1 days but survive for 22 ± 3, 34 ± 2, or 41 ± 8 days after 7, 14, or 21 days of CsA treatment (15 mg/kg per day subcutaneously), respectively (p < 0.001). Animals treated daily for 4 weeks died from drug toxicity; however, an initial 2-week course followed by a low maintenance dose (15 mg/kg every fourth day) produced indefinite (>150 days) graft acceptance without side effects. The long-surviving grafts were supple, grew long hair, and showed normal histology. When the drug was stopped at any time during this maintenance period, early signs of rejection (hair loss, epidermal breakdown, and localized ulceration) occurred, which could be reversed completely by a short CsA 'pulse' (15 mg/kg per day for 7 days). These experimental data support the potential application of CsA immunosuppression in human skin allotransplantation.

Original languageEnglish (US)
Pages (from-to)268-274
Number of pages7
JournalPlastic and Reconstructive Surgery
Volume77
Issue number2
StatePublished - 1986
Externally publishedYes

Fingerprint

Cyclosporine
Allografts
Transplants
Immunosuppression
Skin
Survival
Skin Transplantation
Alopecia
Organ Transplantation
Norway
Immunosuppressive Agents
Hair
Histology
Maintenance
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Towpik, E., Kupiec-Weglinski, J. W., Tyler, D., Araujo, J. L., Schneider, T. M., Araneda, D., ... Tilney, N. L. (1986). Cyclosporine and experimental skin allografts: Long-term survival in rats treated with low maintenance doses. Plastic and Reconstructive Surgery, 77(2), 268-274.

Cyclosporine and experimental skin allografts : Long-term survival in rats treated with low maintenance doses. / Towpik, E.; Kupiec-Weglinski, J. W.; Tyler, Douglas; Araujo, J. L.; Schneider, T. M.; Araneda, D.; Murphy, G. M.; Tilney, N. L.

In: Plastic and Reconstructive Surgery, Vol. 77, No. 2, 1986, p. 268-274.

Research output: Contribution to journalArticle

Towpik, E, Kupiec-Weglinski, JW, Tyler, D, Araujo, JL, Schneider, TM, Araneda, D, Murphy, GM & Tilney, NL 1986, 'Cyclosporine and experimental skin allografts: Long-term survival in rats treated with low maintenance doses', Plastic and Reconstructive Surgery, vol. 77, no. 2, pp. 268-274.
Towpik, E. ; Kupiec-Weglinski, J. W. ; Tyler, Douglas ; Araujo, J. L. ; Schneider, T. M. ; Araneda, D. ; Murphy, G. M. ; Tilney, N. L. / Cyclosporine and experimental skin allografts : Long-term survival in rats treated with low maintenance doses. In: Plastic and Reconstructive Surgery. 1986 ; Vol. 77, No. 2. pp. 268-274.
@article{a5f38179cbf342ff9f67b793fefabbb9,
title = "Cyclosporine and experimental skin allografts: Long-term survival in rats treated with low maintenance doses",
abstract = "Although cyclosporine (CsA) is a powerful immunosuppressive agent in organ transplantation, its efficacy in skin transplantation has not been examined completely. We have tested it as primary immunosuppression in a rat skin allograft model. Histoincompatible Brown-Norway skin grafts are rejected in untreated Lewis hosts within 9 ± 1 days but survive for 22 ± 3, 34 ± 2, or 41 ± 8 days after 7, 14, or 21 days of CsA treatment (15 mg/kg per day subcutaneously), respectively (p < 0.001). Animals treated daily for 4 weeks died from drug toxicity; however, an initial 2-week course followed by a low maintenance dose (15 mg/kg every fourth day) produced indefinite (>150 days) graft acceptance without side effects. The long-surviving grafts were supple, grew long hair, and showed normal histology. When the drug was stopped at any time during this maintenance period, early signs of rejection (hair loss, epidermal breakdown, and localized ulceration) occurred, which could be reversed completely by a short CsA 'pulse' (15 mg/kg per day for 7 days). These experimental data support the potential application of CsA immunosuppression in human skin allotransplantation.",
author = "E. Towpik and Kupiec-Weglinski, {J. W.} and Douglas Tyler and Araujo, {J. L.} and Schneider, {T. M.} and D. Araneda and Murphy, {G. M.} and Tilney, {N. L.}",
year = "1986",
language = "English (US)",
volume = "77",
pages = "268--274",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Cyclosporine and experimental skin allografts

T2 - Long-term survival in rats treated with low maintenance doses

AU - Towpik, E.

AU - Kupiec-Weglinski, J. W.

AU - Tyler, Douglas

AU - Araujo, J. L.

AU - Schneider, T. M.

AU - Araneda, D.

AU - Murphy, G. M.

AU - Tilney, N. L.

PY - 1986

Y1 - 1986

N2 - Although cyclosporine (CsA) is a powerful immunosuppressive agent in organ transplantation, its efficacy in skin transplantation has not been examined completely. We have tested it as primary immunosuppression in a rat skin allograft model. Histoincompatible Brown-Norway skin grafts are rejected in untreated Lewis hosts within 9 ± 1 days but survive for 22 ± 3, 34 ± 2, or 41 ± 8 days after 7, 14, or 21 days of CsA treatment (15 mg/kg per day subcutaneously), respectively (p < 0.001). Animals treated daily for 4 weeks died from drug toxicity; however, an initial 2-week course followed by a low maintenance dose (15 mg/kg every fourth day) produced indefinite (>150 days) graft acceptance without side effects. The long-surviving grafts were supple, grew long hair, and showed normal histology. When the drug was stopped at any time during this maintenance period, early signs of rejection (hair loss, epidermal breakdown, and localized ulceration) occurred, which could be reversed completely by a short CsA 'pulse' (15 mg/kg per day for 7 days). These experimental data support the potential application of CsA immunosuppression in human skin allotransplantation.

AB - Although cyclosporine (CsA) is a powerful immunosuppressive agent in organ transplantation, its efficacy in skin transplantation has not been examined completely. We have tested it as primary immunosuppression in a rat skin allograft model. Histoincompatible Brown-Norway skin grafts are rejected in untreated Lewis hosts within 9 ± 1 days but survive for 22 ± 3, 34 ± 2, or 41 ± 8 days after 7, 14, or 21 days of CsA treatment (15 mg/kg per day subcutaneously), respectively (p < 0.001). Animals treated daily for 4 weeks died from drug toxicity; however, an initial 2-week course followed by a low maintenance dose (15 mg/kg every fourth day) produced indefinite (>150 days) graft acceptance without side effects. The long-surviving grafts were supple, grew long hair, and showed normal histology. When the drug was stopped at any time during this maintenance period, early signs of rejection (hair loss, epidermal breakdown, and localized ulceration) occurred, which could be reversed completely by a short CsA 'pulse' (15 mg/kg per day for 7 days). These experimental data support the potential application of CsA immunosuppression in human skin allotransplantation.

UR - http://www.scopus.com/inward/record.url?scp=0022589613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022589613&partnerID=8YFLogxK

M3 - Article

C2 - 3511482

AN - SCOPUS:0022589613

VL - 77

SP - 268

EP - 274

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 2

ER -